In addition, in the DESTINY-Breast06 study, around 17% of patients were classified as having so-called HER2ultra-low expression, representing a HER2-low disease with faint, incomplete membrane staining of 1 + in ≤ 10% of tumor cells. This evidence concerns the gene ERBB2 and neoplasm.